Investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown for the first time that a combination of targeted therapies with immunotherapy addresses a major cause of treatment resistance in pancreatic cancer.
A study, led by researchers at the Johns Hopkins Kimmel Cancer Center, that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall tumor mutation burden, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors continuously visible to the immune system and predisposing them to respond to immunotherapy.
Inhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T cell and other immune checkpoint therapies, according to a study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute suggests a way to re-energize critical killer immune cells that have become exhausted when fighting cancer or chronic viral infections.
Moffitt Cancer Center researchers, led by cancer biologist Eric Lau, demonstrated how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase tumor infiltrating lymphocytes, promote antitumor immunity, and improve the efficacy of immunotherapy.
A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a phase III clinical trial for metastatic pancreatic ductal adenocarcinoma.
According to a large study led by researchers at the American Cancer Society, the risk of suicide for individuals diagnosed with cancer in the United States is 26% higher, compared with the general population.
A MUSC Hollings Cancer Center pilot trial evaluating brief tele-cognitive behavioral therapy developed specifically for head and neck cancer survivors with body-image distress showed promising results.
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival time for patients with advanced biliary tract cancers, but it may provide a benefit for subsets of patients with locally-advanced disease or gallbladder adenocarcinoma.
